Aranesp (darbepoetin alfa)
View the Aranesp Prescribing Information and Medication Guide at DailyMed.
REMS last update: 12/31/2013
View Aranesp's Regulatory Information at Drugs@FDA
What do participants need to know?
Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the product-specific REMS website or the approved REMS materials for more information.
Healthcare Providers who prescribe Aranesp to patients with cancer
|To be able to prescribe Aranesp||
|Before writing the first prescription for a patient||
|Before writing each prescription after the first prescription||
Patients with cancer who receive Aranesp
|To be able to receive Aranesp||
|Before receiving the initial Aranesp prescription||
Hospitals or outpatient facilities affiliated with hospital/institution that dispense Aranesp to patients with cancer
|To be able to dispense Aranesp||
|Before dispensing Aranesp||
Private-practice-based clinics that dispense Aranesp to patients with cancer
What materials are included in the REMS?
The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers:
Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.